Across TCGA pan-cancer cohorts, FLCN Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FLCN data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher FLCN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FLCN expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
READ, ACC, and UCEC are the cancer types where FLCN Mutation most reproducibly stratifies survival.